Literature DB >> 17029280

Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples.

Nicolas Wentzensen1, Monika Hampl, Matthias Herkert, Anja Reichert, Marcus J Trunk, Christopher Poremba, Ruediger Ridder, Magnus von Knebel Doeberitz.   

Abstract

BACKGROUND: Current cervical cancer screening approaches are based on cytology supplemented by human papillomavirus (HPV) testing in some settings. Whereas cytology is laborious and depends on the cytologists' experience, HPV testing has limited specificity when it is used to detect high-grade lesions. A dichotomous test to identify high-grade lesions with greater specificity may be a useful tool for cervical cancer screening. p16(INK4a) is a cell-cycle regulator that has demonstrated strong overexpression in cervical precancer cells and cervical cancer induced by the deregulated expression of HPV oncogenes.
METHODS: The authors used a sandwich enzyme-linked immunosorbent assay (ELISA) to quantify the amount of solubilized p16(INK4a) protein in lysates that were prepared from cervical samples to detect high-grade cervical lesions. In total, 187 specimens that were obtained after sampling for conventional cytology in women who attended a cervical colposcopy clinic were analyzed. Seventy-six women underwent a biopsy, and 45 of those women showed histologically confirmed, high-grade cervical intraepithelial neoplasia.
RESULTS: For 76 women with biopsy-proven diagnoses, receiver operating characteristic (ROC) analysis of different cutoff values showed an area under the ROC curve of 0.89 for the detection of high-grade cervical dysplasia. At a cutoff value of 8 U/mL, the sensitivity of the p16(INK4a) ELISA for detecting high-grade dysplastic cervical lesions was 96%.
CONCLUSIONS: The data obtained in this study suggested that ELISA-based quantification of solubilized p16(INK4a) protein may have high sensitivity for detecting cervical precancer. Further population-based studies will be necessary to analyze the specificity and predictive values of p16(INK4a) protein quantification in cervical samples. (c) 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17029280     DOI: 10.1002/cncr.22247

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.

Authors:  D C Rijkaart; D A M Heideman; V M H Coupe; A A T P Brink; R H M Verheijen; H Skomedal; F Karlsen; E Morland; P J F Snijders; C J L M Meijer
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

Review 2.  Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.

Authors:  Kate Cuschieri; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10       Impact factor: 4.254

3.  Early detection of cervical carcinomas: finding an overall approach.

Authors:  Nicolas Wentzensen; Stefanie J Klug
Journal:  Dtsch Arztebl Int       Date:  2008-09-12       Impact factor: 5.594

4.  ELISA test to detect CDKN2A (p16(INK4a)) expression in exfoliative cells: a new screening tool for cervical cancer.

Authors:  Li Ding; Xian-Jin Zou; Jin-E Ao; Ai-Xiang Yao; Lan Cai
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

5.  [Human papillomaviruses in the pathogenesis of intraepithelial neoplasia (AIN) and carcinoma of the anus].

Authors:  M von Knebel Doeberitz; M Reuschenbach
Journal:  Hautarzt       Date:  2010-01       Impact factor: 0.751

6.  Identification and validation of genes involved in cervical tumourigenesis.

Authors:  Thangarajan Rajkumar; Kesavan Sabitha; Neelakantan Vijayalakshmi; Sundersingh Shirley; Mayil Vahanan Bose; Gopisetty Gopal; Ganesharaja Selvaluxmy
Journal:  BMC Cancer       Date:  2011-02-22       Impact factor: 4.430

7.  Should LSIL with ASC-H (LSIL-H) in cervical smears be an independent category? A study on SurePath specimens with review of literature.

Authors:  Vinod B Shidham; Nidhi Kumar; Raj Narayan; Gregory L Brotzman
Journal:  Cytojournal       Date:  2007-03-20       Impact factor: 2.091

8.  Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer.

Authors:  Ana María Espinosa; Ana Alfaro; Edgar Roman-Basaure; Mariano Guardado-Estrada; Ícela Palma; Cyntia Serralde; Ingrid Medina; Eligia Juárez; Miriam Bermúdez; Edna Márquez; Manuel Borges-Ibáñez; Sergio Muñoz-Cortez; Avissai Alcántara-Vázquez; Patricia Alonso; José Curiel-Valdez; Susana Kofman; Nicolas Villegas; Jaime Berumen
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

9.  E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease.

Authors:  Heather Griffin; Zhonglin Wu; Rebecca Marnane; Vincent Dewar; Anco Molijn; Wim Quint; Christine Van Hoof; Frank Struyf; Brigitte Colau; David Jenkins; John Doorbar
Journal:  PLoS One       Date:  2012-12-03       Impact factor: 3.240

10.  Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study.

Authors:  Tara J Wu; Karen Smith-McCune; Miriam Reuschenbach; Magnus von Knebel Doeberitz; May Maloba; Megan J Huchko
Journal:  BMJ Open       Date:  2016-09-13       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.